Semorinemab（Cat No.:I042198）is a monoclonal antibody targeting the tau protein, which forms abnormal tangles in the brain and is implicated in neurodegenerative diseases, particularly Alzheimer’s disease. By binding to tau, semorinemab aims to prevent the spread of tau pathology and potentially slow disease progression. It is currently being investigated in clinical trials as a treatment for Alzheimer’s and other tau-related conditions. The drug’s goal is to reduce cognitive decline and improve brain function by addressing one of the key hallmarks of neurodegeneration in these disorders.
